

May 22, 2020

Via E-Mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Drug Introduction Report Pursuant to 18 V.S.A. §4637(c)

To the Office of Attorney General:

On May 5, 2020, ThePharmaNetwork, LLC ("ThePharmaNetwork") introduced the following drug into the market:

NDC Number	Drug Product Description
53097-0568-60	Marinol 2.5 mg, 60 capsules in 1 bottle

Pursuant to 18 V.S.A. §4637(c), ThePharmaNetwork provides the following additional product information listed below.

1. US and international marketing and pricing plans used at launch
 - a. Because this information is not in the public domain or publicly available and is confidential, ThePharmaNetwork declines to provide this information in accordance with 18 V.S.A. §4637(d).
2. Estimated volume of patients
 - a. The estimated number of patients who may be prescribed Marinol is not in the public domain, not publicly available, and is confidential. Additionally, ThePharmaNetwork does not have any information on the estimated volume of patients.
3. Whether the FDA granted breakthrough therapy designation or priority review
 - a. Neither breakthrough therapy designation nor priority review was granted by the FDA.
4. Date and price of acquisition
 - a. This is inapplicable – ThePharmaNetwork did not acquire the product from another manufacturer.

Please feel free to contact me if you have any questions and/or require any additional information.

James Giuliano